In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Stephanie Iyer, PhD, CPP, BCACP, a clinical pharmacist at University of North Carolina neurology clinic, presenting on management of High-risk multiple sclerosis patients, discussed what the pharmacist's role is in managing high-risk MS patients.
In an interview with Pharmacy Times at the Consortium of Multiple Sclerosis Centers 2026, Stephanie Iyer, PhD, CPP, BCACP, a clinical pharmacist at University of North Carolina neurology clinic presenting on management of High-risk multiple sclerosis patients, discussed safety, treatment, and emerging strategies.
Joe DePinto of McKesson outlines the workflow barriers slowing CGT migration to community oncology, the reimbursement reforms needed to scale access, and the pharmacist’s pivotal role in making it all work.
Joe DePinto of McKesson discusses how payers, providers, and employers diverge on CGT reimbursement—and why outcomes-based payment models may hold the key to broader patient access.
Adding immune checkpoint inhibitors to carboplatin and paclitaxel has become the new frontline standard for advanced or recurrent endometrial cancer.
This week's episode covers the White House's expansion of the TrumpRx.gov platform, the pharmacist's critical role in closing adult hepatitis B vaccination gaps, and new FDA approvals in immunology, oncology, and cardiovascular care.
Natalie Bellini, DNP, FNP-BC, BC-ADM, breaks down how updated ADA guidelines have broadened eligibility for continuous glucose monitors, automated insulin delivery systems, and continuous ketone monitoring.
Discover how pharmacists drive biomarker testing, speed therapy approvals, and guide safer immunotherapy decisions in endometrial
Pharmacists boost biomarker testing access and education, streamline therapy approvals, and guide safe immunotherapy dosing in endometrial cancer through proactive IRAE monitoring.
On World Schizophrenia Day, a psychiatric pharmacist details how EHR fragmentation drives medication errors in schizophrenia care, and why provider recognition is essential to fixing it.
Susan Cornell, PharmD, CDCES, FAPhA, FADCES, explains how pharmacists should approach continuous glucose monitoring (CGM) report review and explains why individualized patient education is key.
GLP-1 receptor agonists, molecular profiling, and biomarker-driven treatment strategies may help improve outcomes and personalize care for patients at risk for or diagnosed with endometrial cancer.
Amy Hess-Fischl, MS, RDN, LDN, BC-ADM, CDCES, explains how pharmacists can better leverage underutilized continuous glucose monitoring (CGM) app features and address the education gaps that prevent patients from achieving long-term CGM persistence.
Pharmacists can use immunization registry data, collaborative practice agreements, and evidence-based vaccine advocacy to close adult hepatitis B care gaps.
Pharmacy Times speaks with Jeff Goad, PhD, MPH, a professor of pharmacy practice at Chapman University, on the role pharmacists play during outbreaks or rising measles cases.
Expert highlights why hepatitis B vaccination remains an urgent priority for adult patients and why the 2-dose Heplisav-B regimen's faster seroprotection offers meaningful public health advantages over the traditional 3-dose series.
Nicole C. Pezzino, PharmD, BCACP, CDCES, explains why reimbursement gaps, workflow constraints, and the emotional burden of wearing a continuous glucose monitor (CGM) are limiting CGM success and how pharmacists can improve outcomes.
Pharmacy Times speaks with Jeff Goad, PhD, MPH, about the biggest misconceptions surrounding measles and the MMR vaccine, as well as the serious symptoms pharmacists believe patients should never ignore.
Prior authorizations, injection site shortages, and care transition failures are undermining LAI antipsychotic adherence in patients with schizophrenia, one pharmacist explains.
Pharmacists drive new cholesterol care: educate patients, tackle prior auth and cost barriers, and improve adherence to statins and
Pharmacists speed cholesterol guideline adoption through patient education, prior auth support, and adherence fixes for
Jessica Geiger, PharmD, weighs ketamine in palliative care—pain relief, opioid-sparing evidence, stigma, and safety considerations for hospice patients.
Diana Isaacs, PharmD, BCACP, BC-ADM, CDCES, FADCES, FCCP, explores the most significant advancements in continuous glucose monitoring (CGM) and automated insulin delivery in 2026.
Pharmacy Times interviews Sarah Spark, MHA, MBA, Director of Clinical Data Quality at Ontada, on how clinically relevant edit checks are improving the accuracy and reliability of real-world oncology data to better support clinical decision-making, research, and patient outcomes.
Emerging evidence surrounding GLP-1 receptor agonists and progestin therapies could influence preventive care strategies and endometrial cancer risk reduction in high-risk patients.
Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, discusses how continuous glucose monitoring (CGM) technology and automated insulin delivery systems are transforming pharmacists’ roles.
Pharmacy Times interviews Helen Latimer, MPH, about new real-world data examining racial disparities and evolving trends in HRR genetic testing among patients with metastatic prostate cancer and the implications for equitable access to precision oncology care.
Natalie Bellini, DNP, FNP-BC, BC-ADM, explains why continuous glucose monitor (CGM) persistence so often breaks down after initiation and how pharmacists can intervene at the point of dispensing.
Kunz Coyne expresses interest in antimicrobial stewardship discussions at the joint MAD-ID/SIDP meeting as clinicians continue refining their role in practice.
